User:Tocollins/sandbox1

From Wikipedia, the free encyclopedia

Traditional use[edit][edit]

Psychedelics have a long history of use in traditional medicine and traditional religion, for their perceived ability to promote physical and mental healing. In this context, they are often known as entheogens. Native American practitioners using mescaline-containing cacti (most notably peyote, San Pedro, and Peruvian torch) have reported success against alcoholism, and Mazatecpractitioners routinely use psilocybin mushrooms for divination and healing. Ayahuasca, which contains the potent psychedelic DMT, is used in Peru and other parts of South America for spiritual and physical healing as well as in religious festivals.[citation needed]

Examples[edit][edit]

Doses of lysergic acid diethylamide(LSD)

Main article: List of psychedelic drugs

  • File:Brain on lsd.png
    First ever Neuroimaging study done in 2016.
    LSD (Lysergic acid diethylamide, a.k.a acid) is made from a substance found in ergot, which is a fungus that infects rye.
  • Psilocin is a naturally occurring substance found in psilocybin mushrooms and is found in many parts of the world.
  • mescaline is derived from the Mexican peyote and San Pedro cactus and produces similar effects to LSD.
  • DMT (Diemethyltryptamine) is structurally similar to psilocin, an alkaloid found in psilocybin mushrooms. It can be synthesised in the laboratory but is also a naturally occurring component of several plants.
  • DOM is a member of the DOx family of compounds which are known for their high potency, long duration, and mixture of psychedelic and stimulant effects.2
  • 2C-B (4-Bromo-2,5-dimethoxyphenethylamine) is a psychedelic drug first synthesised in 1974. 2C-B is considered both a psychedelic and a mild entactogenic. ‘Entactogen’ means ‘touching within’ and is a term used by psychiatrists to classify MDMA and related drugs.3
  • Peyote (Lophophora williamsii) is the most well-known and potent psychedelic cactus, although the smallest and slowest growing. Instead of growing upward to form a column, it grows as ‘buttons’ low to the ground. It has been used by Native Americans for over 5000 years.4
  • 25-NBOMe (N-methoxybenzyl) is the name for a series of drugs that have psychedelics effects. Reports indicate that there are a number of different versions of NBOMe available – all with differing effects.5

Chemical family vs Characteristic effects[edit][edit]

Tryptamine

Tryptamine, along with other trace amines, is found in the central nervous system of mammals. It is hypothesized to play a role as a neuromodulator on clasical monoamine neurotransmitters, such dopamine, serotonin and norepinephrine (epinephrine). Tryptamine acts as a non-selective serotonin receptor agonist to activate serotonin receptors, and a serotonin-norepinephrine-dopamine releasing agent(SNDRA) to release more monoamine neurotransmitter, with a preference for evoking serotonin and dopamine release over norepinephrine( epinephrine) release.[1][2][3] This chemical class is well documented to cause amphetamine‐like effects, such responses only occur at concentrations multiple orders of magnitude above normal physiological levels.[4]

Phenethylamine

Phenethylamine is also a trace amine but to a lesser extent acts as a neurotransmitter in the human central nervous system. Phenethylamine instead regulates monoamine neurotransmission by binding to trace amine-associated receptor 1 (TAAR1), which plays a significant role in regulating neurotransmission in dopamine, norepinephrine, and serotonin neurons in the CNS and inhibiting vesicular monoamine transporter 2 (VMAT2) in monoamine neurons.[5][6]When VMAT2 is inhibited monoamine neurotransmitters such as dopamine cannot be released into the synapse via typical release mechanisms.[7]

Lysergamides

Amides of lysergic acid are collectively known as lysergamides, and include a number of compounds with potent agonist and/or antagonist activity at various serotonin and dopaminereceptors. LSD is one of many Lysergamides. A wide range of Lysergamides have emerged in recent years, inspired by existing scientific literature. Others, have appeared from chemical research.[8]






  1. ^ W�lfel, Reinhard; Graefe, Karl-Heinz (1992-02). "Evidence for various tryptamines and related compounds acting as substrates of the platelet 5-hydroxytryptamine transporter". Naunyn-Schmiedeberg's Archives of Pharmacology. 345 (2): 129–136. doi:10.1007/bf00165727. ISSN 0028-1298. {{cite journal}}: Check date values in: |date= (help); replacement character in |last= at position 2 (help)
  2. ^ Shimazu, Seiichiro; Miklya, Ildikó (2004-05). "Pharmacological studies with endogenous enhancer substances: β-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 28 (3): 421–427. doi:10.1016/j.pnpbp.2003.11.016. ISSN 0278-5846. {{cite journal}}: Check date values in: |date= (help)
  3. ^ Blough, Bruce E.; Landavazo, Antonio; Partilla, John S.; Baumann, Michael H.; Decker, Ann M.; Page, Kevin M.; Rothman, Richard B. (2014-04-25). "Hybrid Dopamine Uptake Blocker–Serotonin Releaser Ligands: A New Twist on Transporter-Focused Therapeutics". ACS Medicinal Chemistry Letters. 5 (6): 623–627. doi:10.1021/ml500113s. ISSN 1948-5875.
  4. ^ Berry, Mark D. (2004-07). "Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators". Journal of Neurochemistry. 90 (2): 257–271. doi:10.1111/j.1471-4159.2004.02501.x. ISSN 0022-3042. {{cite journal}}: Check date values in: |date= (help)
  5. ^ Miller, Gregory M. (2011). "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity". Journal of Neurochemistry. 116 (2): 164–176. doi:10.1111/j.1471-4159.2010.07109.x. ISSN 1471-4159. PMC 3005101. PMID 21073468.{{cite journal}}: CS1 maint: PMC format (link)
  6. ^ Grandy, Gina (2020-04-23). "Guest editorial". Gender in Management: An International Journal. 35 (3): 257–260. doi:10.1108/gm-05-2020-238. ISSN 1754-2413.
  7. ^ Little, Karley Y.; Krolewski, David M.; Zhang, Lian; Cassin, Bader J. (2003-01). "Loss of Striatal Vesicular Monoamine Transporter Protein (VMAT2) in Human Cocaine Users". American Journal of Psychiatry. 160 (1): 47–55. doi:10.1176/appi.ajp.160.1.47. ISSN 0002-953X. {{cite journal}}: Check date values in: |date= (help)
  8. ^ Brandt, Simon D.; Kavanagh, Pierce V.; Westphal, Folker; Stratford, Alexander; Odland, Anna U.; Klein, Adam K.; Dowling, Geraldine; Dempster, Nicola M.; Wallach, Jason; Passie, Torsten; Halberstadt, Adam L. (2020-04-20). "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1‐cyclopropanoyl‐ d ‐lysergic acid diethylamide (1CP‐LSD)". Drug Testing and Analysis. doi:10.1002/dta.2789. ISSN 1942-7603. {{cite journal}}: line feed character in |title= at position 102 (help)